PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-108.36%
Negative EBIT growth while AVXL is at 63.69%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-9873.13%
Negative operating income growth while AVXL is at 63.69%. Joel Greenblatt would press for urgent turnaround measures.
-16129.65%
Negative net income growth while AVXL stands at 58.15%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-12933.18%
Negative EPS growth while AVXL is at 60.61%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-12933.18%
Negative diluted EPS growth while AVXL is at 60.61%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
24.22%
Share count expansion well above AVXL's 2.26%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.22%
Diluted share count expanding well above AVXL's 2.26%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-18.12%
Negative OCF growth while AVXL is at 89.51%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
0.96%
FCF growth under 50% of AVXL's 89.51%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.71%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-63.71%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-2899.60%
Negative 3Y OCF/share CAGR while AVXL stands at 77.62%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-30244.22%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-30244.22%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-27789.91%
Negative 3Y CAGR while AVXL is 46.32%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-195.85%
Negative equity/share CAGR over 10 years while AVXL stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-195.85%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
20.77%
3Y equity/share CAGR at 50-75% of AVXL's 32.86%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.33%
Negative asset growth while AVXL invests at 125.91%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
14.08%
Positive BV/share change while AVXL is negative. John Neff sees a clear edge over a competitor losing equity.
11.04%
Debt growth far above AVXL's 3.86%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
35.15%
We increase R&D while AVXL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
3110.63%
We expand SG&A while AVXL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.